| Merdod Ghafouri, DO | |
|
7617 Little River Turn Pike, Suite 710, Annandale, VA 22003-2635 | |
| (703) 335-5750 | |
| (571) 358-3941 |
| Full Name | Merdod Ghafouri |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 34 Years |
| Location | 7617 Little River Turn Pike, Annandale, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811925928 | NPI | - | NPPES |
| C08583 | Other | VA | PTAN MHC |
| 00A989V73 | Other | DC | MEDICARE DC |
| C09878 | Other | VA | PTAN WHC |
| C06380 | Other | VA | MEDICARE VA PTAN |
| G00773 | Other | DC | MEDICARE DC PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 0102201022 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Novant Health Uva Health Haymarket Medical Center | Haymarket, VA | Hospital |
| Novant Prince William Medical Center | Manassas, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carient Heart And Vascular, Llc | 4082972468 | 16 |
News Archive
The Hass Avocado Board (HAB) is supporting research to improve understanding of the unique, positive benefits of consuming fresh avocados to human health and nutrition.
Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.
New research from the Monell Center reveals that children begin using olfactory information to help guide their responses to emotionally-expressive faces at about five years of age.
The study demonstrates that muscle weakness experienced by persons with a regulatory protein tropomyosin mutation is directly related to a mechanism by which the mutant tropomyosin modulates contractile speed and force-generation capacity.
Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
› Verified 2 days ago
| Entity Name | Inova Health Care Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952320061 PECOS PAC ID: 2466351093 Enrollment ID: O20040102000644 |
News Archive
The Hass Avocado Board (HAB) is supporting research to improve understanding of the unique, positive benefits of consuming fresh avocados to human health and nutrition.
Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.
New research from the Monell Center reveals that children begin using olfactory information to help guide their responses to emotionally-expressive faces at about five years of age.
The study demonstrates that muscle weakness experienced by persons with a regulatory protein tropomyosin mutation is directly related to a mechanism by which the mutant tropomyosin modulates contractile speed and force-generation capacity.
Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
› Verified 2 days ago
| Entity Name | Carient Heart & Vascular, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669982526 PECOS PAC ID: 4082972468 Enrollment ID: O20171212001016 |
News Archive
The Hass Avocado Board (HAB) is supporting research to improve understanding of the unique, positive benefits of consuming fresh avocados to human health and nutrition.
Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.
New research from the Monell Center reveals that children begin using olfactory information to help guide their responses to emotionally-expressive faces at about five years of age.
The study demonstrates that muscle weakness experienced by persons with a regulatory protein tropomyosin mutation is directly related to a mechanism by which the mutant tropomyosin modulates contractile speed and force-generation capacity.
Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Merdod Ghafouri, DO 8100 Ashton Ave, Suite 200, Manassas, VA 20109-5688 Ph: (703) 335-8750 | Merdod Ghafouri, DO 7617 Little River Turn Pike, Suite 710, Annandale, VA 22003-2635 Ph: (703) 335-5750 |
News Archive
The Hass Avocado Board (HAB) is supporting research to improve understanding of the unique, positive benefits of consuming fresh avocados to human health and nutrition.
Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.
New research from the Monell Center reveals that children begin using olfactory information to help guide their responses to emotionally-expressive faces at about five years of age.
The study demonstrates that muscle weakness experienced by persons with a regulatory protein tropomyosin mutation is directly related to a mechanism by which the mutant tropomyosin modulates contractile speed and force-generation capacity.
Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
› Verified 2 days ago
Thomas Ambrose Mccabe, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: Northern Virginia Pulmonary & Critical Care Assoc. Pc, 3289 Woodburn Road, 350, Annandale, VA 22003 Phone: 703-641-8616 Fax: 703-641-9468 | |
Dr. Allan J. Morrison, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 3289 Woodburn Rd, Suite # 200, Annandale, VA 22003 Phone: 703-560-7900 Fax: 703-560-8408 | |
Dr. John K. Kim, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7700 Little River Tpke Ste 102, Annandale, VA 22003 Phone: 703-752-4623 Fax: 703-762-9978 | |
Aabha Jain, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3289 Woodburn Rd, Suite 200, Annandale, VA 22003 Phone: 703-560-7900 | |
Manisha Reddy, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7432 Little River Tpke, Annandale, VA 22003 Phone: 703-658-7060 | |
Dr. Vishal Mungal, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3289 Woodburn Rd, Annandale, VA 22003 Phone: 703-641-8616 Fax: 703-641-9468 | |
Dr. Stafford S Goldstein, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3301 Woodburn Rd, Suite #107, Annandale, VA 22003 Phone: 703-876-0437 Fax: 703-876-0722 |